5zvn - Revision history

OCA at 17:36, 11 December 2019

OCA — Wed, 11 Dec 2019 17:36:52 GMT

←Older revision		Revision as of 17:36, 11 December 2019
Line 8:		Line 8:
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5zvn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5zvn OCA], [http://pdbe.org/5zvn PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5zvn RCSB], [http://www.ebi.ac.uk/pdbsum/5zvn PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5zvn ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5zvn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5zvn OCA], [http://pdbe.org/5zvn PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5zvn RCSB], [http://www.ebi.ac.uk/pdbsum/5zvn PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5zvn ProSAT]</span></td></tr>
	</table>		</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Indolicidin is a member of cathelicidin family which displays broad spectrum antimicrobial activity. Severe toxicity and aggregation propensity associated with indolicidin pose a huge limitation to its probable therapeutic application. We are reporting the use of glycosylation strategy to design an analogue of indolicidin and subsequently explore structural and functional effects of sugar on it. Our study led to the design of a potent antibacterial glycosylated peptide, [betaGlc-T9,K7]indolicidin, which showed decreased toxicity against erythrocytes and macrophage cells and thus a higher therapeutic selectivity. The incorporation of sugar also increased the solubility of the peptide. The mode of bacterial killing, functional stability, LPS binding, and cytokine inhibitory potential of the peptide, however, seemed unaffected upon glycosylation. Absence of significant changes in structure upon glycosylation accounts for the possibly retained functions and mode of action of the peptide. Our report thus presents the designing of an indolicidin analogue with improved therapeutic potential by substituting aromatic amino acid with glycosylated amino acid as a promising strategy for the first time.
		+
		+	Design of therapeutically improved analogue of the antimicrobial peptide, indolicidin, using a glycosylation strategy.,Dwivedi R, Aggarwal P, Bhavesh NS, Kaur KJ Amino Acids. 2019 Nov;51(10-12):1443-1460. doi: 10.1007/s00726-019-02779-2. Epub , 2019 Sep 4. PMID:31485742<ref>PMID:31485742</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 5zvn" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>

OCA at 05:45, 19 June 2019

OCA — Wed, 19 Jun 2019 05:45:22 GMT

←Older revision		Revision as of 05:45, 19 June 2019
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry 5zvn is ON HOLD until Paper Publication~~	+	==Structure of [beta Glc-T9,K7]indolicidin, a glycosylated analogue of indolicidin==
-		+	<StructureSection load='5zvn' size='340' side='right'caption='[[5zvn]], [[NMR_Ensembles_of_Models \| 20 NMR models]]' scene=''>
-	~~Authors: Dwivedi, R., Aggarwal, P., Kaur, K.J., Bhavesh, N.S.~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[5zvn]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5ZVN OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5ZVN FirstGlance]. <br>
-	~~Description:~~ Structure of [beta Glc-T9,K7]indolicidin, a glycosylated analogue of indolicidin	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BGC:BETA-D-GLUCOSE'>BGC</scene></td></tr>
-	[[~~Category~~: ~~Unreleased Structures~~]]	+	<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=NH2:AMINO+GROUP'>NH2</scene></td></tr>
-	[[~~Category~~: ~~Bhavesh~~, N.S]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5zvn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5zvn OCA], [http://pdbe.org/5zvn PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5zvn RCSB], [http://www.ebi.ac.uk/pdbsum/5zvn PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5zvn ProSAT]</span></td></tr>
		+	</table>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Large Structures]]
	[[Category: Aggarwal, P]]		[[Category: Aggarwal, P]]
		+	[[Category: Bhavesh, N S]]
	[[Category: Dwivedi, R]]		[[Category: Dwivedi, R]]
-	[[Category: Kaur, K.J]]	+	[[Category: Kaur, K J]]
		+	[[Category: Antimicrobial indolicidin derivative]]
		+	[[Category: Antimicrobial protein]]

OCA at 05:45, 20 March 2019

OCA — Wed, 20 Mar 2019 05:45:53 GMT

←Older revision		Revision as of 05:45, 20 March 2019
Line 5:		Line 5:
	Authors: Dwivedi, R., Aggarwal, P., Kaur, K.J., Bhavesh, N.S.		Authors: Dwivedi, R., Aggarwal, P., Kaur, K.J., Bhavesh, N.S.

-	Description: Structure of ~~indW9(~~Glc~~)TP7K~~, a glycosylated ~~analog~~ of indolicidin	+	Description: Structure of [beta Glc-T9,K7]indolicidin, a glycosylated analogue of indolicidin
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
	[[Category: Bhavesh, N.S]]		[[Category: Bhavesh, N.S]]
-	[[Category: Dwivedi, R]]
	[[Category: Aggarwal, P]]		[[Category: Aggarwal, P]]
		+	[[Category: Dwivedi, R]]
	[[Category: Kaur, K.J]]		[[Category: Kaur, K.J]]

OCA at 08:33, 5 September 2018

OCA — Wed, 05 Sep 2018 08:33:25 GMT

←Older revision		Revision as of 08:33, 5 September 2018
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5zvn is ON HOLD	+	The entry 5zvn is ON HOLD until Paper Publication

	Authors: Dwivedi, R., Aggarwal, P., Kaur, K.J., Bhavesh, N.S.		Authors: Dwivedi, R., Aggarwal, P., Kaur, K.J., Bhavesh, N.S.
Line 8:		Line 8:
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
	[[Category: Bhavesh, N.S]]		[[Category: Bhavesh, N.S]]
-	[[Category: Aggarwal, P]]
	[[Category: Dwivedi, R]]		[[Category: Dwivedi, R]]
		+	[[Category: Aggarwal, P]]
	[[Category: Kaur, K.J]]		[[Category: Kaur, K.J]]

OCA: Protected "5zvn" [edit=sysop:move=sysop]

OCA — Wed, 16 May 2018 03:56:57 GMT

Protected "5zvn" [edit=sysop:move=sysop]

←Older revision

Revision as of 03:56, 16 May 2018

OCA: New page: '''Unreleased structure''' The entry 5zvn is ON HOLD Authors: Dwivedi, R., Aggarwal, P., Kaur, K.J., Bhavesh, N.S. Description: Structure of indW9(Glc)TP7K, a glycosylated analog of in...

OCA — Wed, 16 May 2018 03:56:56 GMT

New page: '''Unreleased structure''' The entry 5zvn is ON HOLD Authors: Dwivedi, R., Aggarwal, P., Kaur, K.J., Bhavesh, N.S. Description: Structure of indW9(Glc)TP7K, a glycosylated analog of in...

New page

'''Unreleased structure'''

The entry 5zvn is ON HOLD

Authors: Dwivedi, R., Aggarwal, P., Kaur, K.J., Bhavesh, N.S.

Description: Structure of indW9(Glc)TP7K, a glycosylated analog of indolicidin
[[Category: Unreleased Structures]]
[[Category: Bhavesh, N.S]]
[[Category: Aggarwal, P]]
[[Category: Dwivedi, R]]
[[Category: Kaur, K.J]]